In a move that will make the combined entity the global leader in bioloigical irradiation, Precision X-Ray (PXi) and Faxitron Bioptics are combining their irradiation businesses into a new company, DRMC X-Ray.

DRMC is an affiliate of Faxitron and was formed to take title of the company's irradiation assets. It acquired the assets of PXi today.

Both firms have “have deep roots in cabinet x-ray for biological irradiation,” according to a company statement.

Both businesses also have “highly complementary, innovation-driven cultures,” Paul Murtagh, Chairman of DRMC, noted, adding that, “biological irradiation is imperative to a vast scope of both fundamental and applied research. We look forward to building on the strong foundation of both businesses, as we continue their legacies by providing more advanced systems to further expand the use of X-ray in biological research and other irradiation applications.”

DRMC's corporate headquarters, R&D and manufacturing operations will be at the present PXi home base in North Branford, Connecticut, and will continue to operate under the PXi name.

The new company will have an installed base of over 1,000 systems, and plans new investments in all avenues of its business.

“The X-ray systems and linked applications we provide play a pivotal role in radiation-based oncology, immunology, genetics and agricultural research,” stated Bill McLaughlin, president of PXi, adding that the bigger product range and service footprint and technical expertise “will strengthen the irradiation solutions we can provide to our combined customer base worldwide.”

In May, PXi announced the introduction of the X-RAD 160 qube, a compact cabinet irradiator for cell and tissue irradiation that can be housed directly in a research lab and can sit on a lab bench or a wheeled cart. This permits samples to be irradiated in a sterile lab environment, the company stated.

The 160 qube has a touch screen control and needs “no specialized X-ray training or knowledge,” stated the company.

In late 2017, Faxitron's VersaVision digital specimen radiography system got FDA clearance for imaging core biopsy and surgically excised specimen samples.

The system immediately generates high-quality images and displays them on a high-resolution 24-inch monitor.

"It has been designed to deliver instant imaging and verification of samples, which facilitates an improved clinical experience for providers and patients," Donogh O'Driscoll, chief financial officer and chief operating officer at Faxitron, told HCB News at the time.

Business Affairs Homepage